Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.35 |
| ▸ | CFD | P00746 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25370780 | 1.00 | P2RX7 (0.35) | P2RX7CFDGRIN1GRIN2AALDH1A1 | |
| SCHEMBL26051687 | 0.81 | EPHX2 (0.36) | P2RX7CFDALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL30580204 | 0.80 | CYP3A4 (0.40) | EPHX2 | |
| SCHEMBL25370529 | 0.80 | CYP3A4 (0.40) | EPHX2 | |
| SCHEMBL26050994 | 0.78 | P2RX7 (0.35) | P2RX7CFDGRIN1GRIN2AEPHX2 | |
| SCHEMBL28803365 | 0.76 | CFD (0.39) | P2RX7CFDGRIN1GRIN2AALDH1A1 | |
| SCHEMBL25369595 | 0.76 | ERCC1 (0.46) | MAPK1EPHX2 | |
| SCHEMBL30580137 | 0.76 | ERCC1 (0.46) | MAPK1EPHX2 | |
| SCHEMBL26051685 | 0.74 | ALDH1A1 (0.36) | P2RX7CFDGRIN1GRIN2AALDH1A1 | |
| SCHEMBL25372012 | 0.71 | TRPA1 (0.39) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2025-01-02 | — | — | US | claimed |
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | ANGELINI PHARMA S.P.A. (IT) | 2025-01-02 | — | — | US | disclosed |
| EP-4479377-A1 | NEW BICYCLOPENTANE DERIVATIVES | Icagen, LLC (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-118829626-A | Novel dicyclopentane derivatives | 伊卡根有限责任公司 | 2024-10-22 | — | — | CN | disclosed |
| WO-2023158584-A1 | NEW BICYCLOPENTANE DERIVATIVES | ICAGEN, LLC (US) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002452-A1 | BICYCLOPENTANE DERIVATIVES | BICRA, C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P2RX7 1289/4885CFD 890/4885GRIN1 2140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.